Image Description
Treatment & Prognosis: Primary effusion lymphoma is an aggressive disease with poor prognosis. Despite therapy, median survival is < 6 months.. In cases where the tumor cells express CD38 and initial systemic therapies have failed, the use of daratumumab (anti-CD38 antibody) has produced tumor response and lowering of HHV8 levels.
Image courtesy of: Laura Brown, MD; used with permission.
Image courtesy of: Laura Brown, MD; used with permission.